Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032773 · ClinicalTrials.gov registry record · Phase 1
Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
A Phase 1 study, sponsored by Astex Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00032773 is a Phase 1 study that was terminated before completion, run by Astex Pharmaceuticals. The registered enrollment target is 36 participants.
The verdict
NCT00032773, a Phase 1 study, was terminated before completion, sponsored by Astex Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to identify the minimal effective dose of pentostatin defined as the lowest dose that produces a response in 20% or more of patients while producing treatment failure (defines as death, grade 3/4 toxicity, or progressive disease) in 40% or less of patients.
Interventions
- DRUG pentostatin for injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2002-01-30 |
| Est. Completion | 2005-11-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00032773
The ClinicalTrials.gov registry entry for NCT00032773 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pentostatin for injection is the first listed.
NCT00032773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00032773 about?
NCT00032773 is a clinical study titled "Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD". To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to identify the minimal effective dose of pentostatin defined as the lowest dose that produces a response in 20% or more of patients while producing treatment failure (defines as death, grade 3/4 toxicity, or progr...
What is the current status of trial NCT00032773?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2002-01-30. Estimated completion is 2005-11-03.
What interventions are being tested in trial NCT00032773?
The interventions under investigation include: pentostatin for injection (DRUG).
Who is sponsoring clinical trial NCT00032773?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.